WHO ICTRP trial
Ultra high field 7.0 Tesla MR Spectroscopy to monitor capecitabine metabolism in…
EUCTR2016-000092-24-NL · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2016-000092-24-NL |
|---|---|
| Public title | Ultra high field 7.0 Tesla MR Spectroscopy to monitor capecitabine metabolism in liver metastases – a proof of concept study |
| Scientific title | The PLCRC substudy Ultra high field 7.0 Tesla MR Spectroscopy to monitor capecitabine metabolism in liver metastases – a proof of concept study - The PLCRC - SPECTRE study |
| Primary sponsor | University Medical Center Utrecht |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): yes Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Netherlands |
| Conditions | Colorectal carcinoma MedDRA version: 19.0 Level: LLT Classification code 10010036 Term: Colorectal carcinoma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Trade Name: Capecitabine Pharmaceutical Form: Tablet |
| Registration date | Mar 16, 2016 |
| Secondary IDs | 56286 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: